Invex TherapeuticsASX:IXC -9.09% 9-Day RSI is 31.01 as of Jun. 28, 2026. The stock has 1 warning sign investors should review. Among 1,423 Biotechnology companies, Invex Therapeutics ranks better than 79.27% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Invex Therapeutics 9-Day RSI Related Terms
ASX:IXC vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Invex Therapeutics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invex Therapeutics 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invex Therapeutics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Invex Therapeutics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invex Therapeutics (ASX:IXC) has a 9-Day RSI of 31.01 as of Jun. 28, 2026. According to the industry distribution chart, Invex Therapeutics ranks #295 out of 1423 companies in the Biotechnology industry, placing it in the top 20.7%.
Is Invex Therapeutics' 9-Day RSI too high?
Invex Therapeutics' current 9-Day RSI is 31.01. The Biotechnology industry median 9-Day RSI is 45.82. Invex Therapeutics' value of 31.01 is 32.3% below this industry median. Based on the distribution chart, Invex Therapeutics ranks #295 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Invex Therapeutics' 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #295 out of 1423 companies for 9-Day RSI. This places Invex Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 45.82. Invex Therapeutics' value of 31.01 is 32.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 45.82, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invex Therapeutics's current 9-Day RSI of 31.01 is 32.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 45.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invex Therapeutics's current 9-Day RSI is 31.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current 9-Day RSI of 31.01. The current 9-Day RSI is 31.01 and 32.3% below the Biotechnology industry median of 45.82. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current 9-Day RSI is 31.01 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IXC has been successfully added to your